LCOR

Summary

LCOR (ligand dependent nuclear receptor corepressor, HGNC:29503) is a protein-coding gene on chromosome 10q24.1, encoding Ligand-dependent corepressor (Q96JN0). May act as transcription activator that binds DNA elements with the sequence 5’-CCCTATCGATCGATCTCTACCT-3'.

LCOR is a transcriptional corepressor widely expressed in fetal and adult tissues that is recruited to agonist-bound nuclear receptors through a single LxxLL motif, also referred to as a nuclear receptor (NR) box (Fernandes et al., 2003 [PubMed 12535528]).

Source: NCBI Gene 84458 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 60 total
• MANE Select transcript: NM_001346516

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29503
Approved symbol	LCOR
Name	ligand dependent nuclear receptor corepressor
Location	10q24.1
Locus type	gene with protein product
Status	Approved
Aliases	MLR2, FLJ38026, KIAA1795, DKFZP564P1916, FLJ13022
Ensembl gene	ENSG00000196233
Ensembl biotype	protein_coding
OMIM	607698
Entrez	84458

Gene structure

Transcript identifiers

Ensembl transcripts: 36 — 23 protein_coding, 9 nonsense_mediated_decay, 2 protein_coding_CDS_not_defined, 2 retained_intron

ENST00000356016, ENST00000371097, ENST00000371103, ENST00000421806, ENST00000463415, ENST00000469510, ENST00000493486, ENST00000540664, ENST00000674725, ENST00000674796, ENST00000675117, ENST00000675125, ENST00000675151, ENST00000675250, ENST00000675251, ENST00000675471, ENST00000675537, ENST00000675687, ENST00000675902, ENST00000675915, ENST00000675971, ENST00000676067, ENST00000676123, ENST00000676187, ENST00000676257, ENST00000676314, ENST00000676373, ENST00000676381, ENST00000676414, ENST00000874571, ENST00000874572, ENST00000874573, ENST00000931941, ENST00000931942, ENST00000931943, ENST00000931944

RefSeq mRNA: 4 — MANE Select: NM_001346516 NM_001170765, NM_001170766, NM_001346516, NM_032440

CCDS: CCDS53561, CCDS7451, CCDS86132

Canonical transcript exons

ENST00000421806 — 8 exons

Exon	Start	End
ENSE00001097431	96907668	96907747
ENSE00001097435	96944113	96944245
ENSE00001097437	96907265	96907330
ENSE00001139835	96833406	96833479
ENSE00001414342	96949008	96949295
ENSE00001661157	96980793	96995956
ENSE00002222993	96832298	96832399
ENSE00003592556	96952103	96952196

Expression profiles

Bgee: expression breadth ubiquitous, 258 present calls, max score 98.71.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 18.6332 / max 303.6484, expressed in 1797 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
106413	14.7035	1784
106414	1.4521	790
106412	1.0162	392
106416	0.7165	422
106415	0.6104	315
106411	0.1158	50
106419	0.0189	10

Top tissues by expression

273 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	98.71	gold quality
oocyte	CL:0000023	98.02	gold quality
jejunal mucosa	UBERON:0000399	97.28	gold quality
mucosa of paranasal sinus	UBERON:0005030	97.24	gold quality
ileal mucosa	UBERON:0000331	96.63	gold quality
jejunum	UBERON:0002115	96.61	gold quality
visceral pleura	UBERON:0002401	95.48	gold quality
cardia of stomach	UBERON:0001162	95.05	gold quality
pylorus	UBERON:0001166	94.76	gold quality
renal medulla	UBERON:0000362	94.73	gold quality
nipple	UBERON:0002030	94.49	gold quality
mucosa of sigmoid colon	UBERON:0004993	94.21	gold quality
inferior vagus X ganglion	UBERON:0005363	93.96	gold quality
bronchial epithelial cell	CL:0002328	93.73	gold quality
colonic mucosa	UBERON:0000317	93.61	gold quality
parietal pleura	UBERON:0002400	93.51	gold quality
epithelium of bronchus	UBERON:0002031	93.33	gold quality
bronchus	UBERON:0002185	93.32	gold quality
superior surface of tongue	UBERON:0007371	93.26	gold quality
penis	UBERON:0000989	93.25	gold quality
epithelium of nasopharynx	UBERON:0001951	93.22	gold quality
corpus callosum	UBERON:0002336	93.01	gold quality
pancreatic ductal cell	CL:0002079	92.87	gold quality
urethra	UBERON:0000057	92.80	gold quality
amniotic fluid	UBERON:0000173	92.54	gold quality
palpebral conjunctiva	UBERON:0001812	92.45	gold quality
adrenal tissue	UBERON:0018303	92.13	gold quality
pharyngeal mucosa	UBERON:0000355	92.06	gold quality
bone marrow	UBERON:0002371	91.89	gold quality
trabecular bone tissue	UBERON:0002483	91.85	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.26

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

2 targets.

Target	Regulation
CDH1	Unknown
CDKN1A	Unknown

Upstream regulators (CollecTRI, top): KLF6, RARA

miRNA regulators (miRDB)

543 targeting LCOR, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-196A-5P	100.00	68.16	684
HSA-MIR-196B-5P	100.00	68.16	681
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3646	100.00	73.56	5283
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-3162-3P	100.00	65.37	363
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-574-5P	100.00	66.01	989
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-3163	100.00	77.23	8605

Literature-anchored findings (GeneRIF, showing 11)

• Data show that LCoR (ligand-dependent nuclear receptor corepressor) represents a class of corepressor that attenuates agonist-activated nuclear receptor signaling by multiple mechanisms [Ligand-dependent nuclear receptor corepressor]. (PMID:12535528)
• HDAC6 can function as a cofactor of LCoR but they can act to enhance expression of specific estrogen-regulated genes (PMID:19744931)
• role for LCoR and CtBP1 as attenuators of progesterone-regulated transcription, but LCoR and CtBP1 can act to enhance transcription of some genes (PMID:19744932)
• These results showed that the presence of miR-615-3p repressed the expression of LCoR, a derepressor of peroxisome proliferator-activated receptor gamma (PPARgamma). (PMID:21565892)
• Ligand-dependent corepressor acts as a novel androgen receptor corepressor, inhibits prostate cancer growth, and is functionally inactivated by the Src protein kinase. (PMID:21856747)
• LCoR recruitment by KLF6 regulates expression of the cyclin-dependent kinase inhibitor CDKN1A gene. (PMID:22277651)
• Taken together, these results provide new insights into the mechanism of action of LCoR and RIP140 and highlight their strong interplay for the control of gene expression and cell proliferation in breast cancer cells. (PMID:28414308)
• miR-199a promotes stem cell properties in mammary stem cells and breast cancer stem cells by directly repressing nuclear receptor corepressor LCOR, which primes interferon responses. (PMID:28530657)
• C10ORF12 protein functions as a positive regulator of PRC2 and facilitates PRC2-mediated H3K27me3 modification of chromatin. (PMID:31186533)
• A decrease of nuclear LCoR expression in line with an increase of dedifferentiation of CIN can be observed. Nuclear LCoR overexpression correlates with CIN II progression indicating a prognostic value of LCoR in cervical intraepithelial neoplasia (PMID:32157438)
• The Expression of NRIP1 and LCOR in Endometrioid Endometrial Cancer. (PMID:34410950)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Lcor	ENSMUSG00000025019
rattus_norvegicus	Lcor	ENSRNOG00000042679

Paralogs (1): LCORL (ENSG00000178177)

Protein

Protein identifiers

Ligand-dependent corepressor — Q96JN0 (reviewed: Q96JN0)

Alternative names: Mblk1-related protein 2

All UniProt accessions (17): Q96JN0, A0A6Q8PFF1, A0A6Q8PFM6, A0A6Q8PFM9, A0A6Q8PFQ9, A0A6Q8PFV7, A0A6Q8PG56, A0A6Q8PG71, A0A6Q8PG83, A0A6Q8PGD6, A0A6Q8PGL8, A0A6Q8PGP3, A0A6Q8PGQ5, A0A6Q8PGR8, A0A6Q8PGV7, A0A6Q8PH28, A0A6Q8PHQ4

UniProt curated annotations — full annotation on UniProt →

Function. May act as transcription activator that binds DNA elements with the sequence 5’-CCCTATCGATCGATCTCTACCT-3’. Repressor of ligand-dependent transcription activation by target nuclear receptors. Repressor of ligand-dependent transcription activation by ESR1, ESR2, NR3C1, PGR, RARA, RARB, RARG, RXRA and VDR.

Subunit / interactions. Interacts with ESR1 and ESR2 in the presence of estradiol. Interacts with CTBP1, HDAC3 and HDAC6. Component of a large corepressor complex that contains about 20 proteins, including CTBP1, CTBP2, HDAC1 and HDAC2.

Subcellular location. Nucleus.

Tissue specificity. Ubiquitous.

Isoforms (3)

UniProt ID	Names	Canonical?
Q96JN0-1	1	yes
Q96JN0-2	2
Q96JN0-3	3

RefSeq proteins (4): NP_001164236, NP_001164237, NP_001333445, NP_115816 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007889	HTH_Psq	Domain
IPR009057	Homeodomain-like_sf	Homologous_superfamily

Pfam: PF05225

UniProt features (42 total): modified residue 11, cross-link 6, compositionally biased region 4, sequence conflict 4, region of interest 4, splice variant 3, helix 3, short sequence motif 2, chain 1, domain 1, DNA-binding region 1, mutagenesis site 1, turn 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
6V3Y	X-RAY DIFFRACTION	1.63
6V3X	X-RAY DIFFRACTION	1.7
9WRJ	X-RAY DIFFRACTION	2.2
2COB	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96JN0-F1	55.80	0.13

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (17): 42, 63, 249, 254, 414, 583, 605, 792, 1048, 1077, 1214, 1219, 1274, 345, 391, 543, 976

Mutagenesis-validated functional residues (1):

Position	Phenotype
56–57	loss of estradiol-dependent interaction with esr1 and esr2.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 373 (showing top): ACTACCT_MIR196A_MIR196B, GOBP_RESPONSE_TO_ESTRADIOL, GOBP_CELLULAR_RESPONSE_TO_LIPID, AP2_Q3, GGGTGGRR_PAX4_03, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GTGCCTT_MIR506, GOBP_NEGATIVE_REGULATION_OF_GENE_EXPRESSION_EPIGENETIC, CEBP_Q2, MODULE_205, GATA3_01, GATA1_01, WTGAAAT_UNKNOWN, TGIF_01, ATTACAT_MIR3803P

GO Biological Process (3): negative regulation of transcription by RNA polymerase II (GO:0000122), regulation of transcription by RNA polymerase II (GO:0006357), cellular response to estradiol stimulus (GO:0071392)

GO Molecular Function (8): transcription corepressor binding (GO:0001222), DNA binding (GO:0003677), transcription corepressor activity (GO:0003714), nuclear estrogen receptor binding (GO:0030331), histone deacetylase binding (GO:0042826), histone methyltransferase binding (GO:1990226), ubiquitin-specific protease binding (GO:1990381), protein binding (GO:0005515)

GO Cellular Component (2): nucleus (GO:0005634), nucleoplasm (GO:0005654)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transcription by RNA polymerase II	2
negative regulation of DNA-templated transcription	2
enzyme binding	2
regulation of transcription by RNA polymerase II	1
regulation of DNA-templated transcription	1
response to estradiol	1
cellular response to lipid	1
cellular response to oxygen-containing compound	1
transcription coregulator binding	1
nucleic acid binding	1
transcription coregulator activity	1
nuclear receptor binding	1
protease binding	1
binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1

Protein interactions and networks

STRING

778 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LCOR	MTF2	Q9Y483	890
LCOR	CTBP1	Q13363	888
LCOR	NRIP1	P48552	832
LCOR	ESR1	P03372	810
LCOR	EPOP	A6NHQ4	799
LCOR	PHF19	Q5T6S3	766
LCOR	AEBP2	Q6ZN18	726
LCOR	KDM1A	O60341	690
LCOR	NCOA2	Q15596	673
LCOR	JARID2	Q92833	666
LCOR	PHF1	O43189	662
LCOR	RBBP4	P31149	592
LCOR	EZH1	Q92800	589
LCOR	PPARG	P37231	573
LCOR	EZH2	Q15910	562

IntAct

218 interactions, top by confidence:

A	B	Type	Score
SUZ12	EZH2	psi-mi:“MI:2364”(proximity)	0.960
EZH2	PHF1	psi-mi:“MI:0914”(association)	0.900
CTBP1	LCOR	psi-mi:“MI:0915”(physical association)	0.890
CTBP2	LCOR	psi-mi:“MI:0915”(physical association)	0.880
LCOR	CTBP2	psi-mi:“MI:0915”(physical association)	0.880
CTBP1	ZEB2	psi-mi:“MI:0914”(association)	0.800
PHF1	EED	psi-mi:“MI:0914”(association)	0.790
RBBP4	CDK2AP1	psi-mi:“MI:0914”(association)	0.790
EZH2	EPOP	psi-mi:“MI:0914”(association)	0.730
CTBP1	CBX4	psi-mi:“MI:0914”(association)	0.700
SUZ12	EPOP	psi-mi:“MI:0914”(association)	0.640
MTF2	EED	psi-mi:“MI:0914”(association)	0.640
LCOR	EHMT2	psi-mi:“MI:0915”(physical association)	0.560
GOLGA2	LCOR	psi-mi:“MI:0915”(physical association)	0.560
TRAF1	LCOR	psi-mi:“MI:0915”(physical association)	0.560
CTBP2	LCOR	psi-mi:“MI:0915”(physical association)	0.560
EED	EPOP	psi-mi:“MI:0914”(association)	0.530
KLHDC3	DPYSL4	psi-mi:“MI:0914”(association)	0.530

BioGRID (283): LCOR (Two-hybrid), LCOR (Two-hybrid), LCOR (Two-hybrid), LCOR (Affinity Capture-MS), LCOR (Affinity Capture-MS), LCOR (Affinity Capture-MS), LCOR (Affinity Capture-MS), LCOR (Affinity Capture-MS), LCOR (Affinity Capture-MS), LCOR (Affinity Capture-MS), LCOR (Affinity Capture-MS), LCOR (Affinity Capture-MS), LCOR (Affinity Capture-MS), LCOR (Affinity Capture-MS), LCOR (Affinity Capture-MS)

ESM2 similar proteins: A0JMA6, A4QNP7, A8TSS9, C0LZJ1, D4A218, F6W2R2, J7FCF0, O42115, O57682, O57685, P32114, P47240, P81068, P83758, Q00288, Q02962, Q19291, Q2I327, Q2MJB4, Q2TAQ8, Q4AE28, Q4V5A3, Q504H8, Q5UU75, Q5VZB9, Q66IK1, Q6DCQ1, Q6F2E3, Q6YHU8, Q6ZPI3, Q71MM5, Q76L87, Q7TST9, Q801F8, Q80WT2, Q86V15, Q8IVH2, Q8JIR6, Q8JJ64, Q90WM5

Diamond homologs: G5EGQ5, Q3U285, Q5ZJK5, Q6ZPI3, Q8N3X6, Q95YM8, Q96JN0

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 190 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Transcriptional Regulation by E2F6	7	14.0×	6e-05
PRC2 methylates histones and DNA	12	12.5×	1e-07
XBP1(S) activates chaperone genes	8	11.8×	4e-05
Regulation of PTEN gene transcription	9	11.0×	3e-05
PKMTs methylate histone lysines	9	9.9×	4e-05
Defective pyroptosis	9	9.6×	4e-05
Negative Regulation of CDH1 Gene Transcription	11	9.1×	1e-05
Oxidative Stress Induced Senescence	10	6.2×	4e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

60 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	50
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2525 predictions. Top by Δscore:

Variant	Effect	Δscore
10:96833480:G:GG	donor_gain	1.0000
10:96852738:G:GT	donor_gain	1.0000
10:96852780:GTCA:G	donor_gain	1.0000
10:96858291:GA:G	acceptor_gain	1.0000
10:96858413:GATT:G	donor_gain	1.0000
10:96858417:G:GG	donor_gain	1.0000
10:96907666:A:AG	acceptor_gain	1.0000
10:96907667:G:GG	acceptor_gain	1.0000
10:96907667:GACT:G	acceptor_gain	1.0000
10:96944241:AAAAG:A	donor_loss	1.0000
10:96944242:AAAG:A	donor_loss	1.0000
10:96944243:AAG:A	donor_loss	1.0000
10:96944245:GGT:G	donor_loss	1.0000
10:96944246:G:T	donor_loss	1.0000
10:96944247:T:G	donor_loss	1.0000
10:96949005:CAGA:C	acceptor_loss	1.0000
10:96949006:A:AC	acceptor_loss	1.0000
10:96949006:A:AG	acceptor_gain	1.0000
10:96949007:G:GA	acceptor_gain	1.0000
10:96949007:GA:G	acceptor_gain	1.0000
10:96949007:GAC:G	acceptor_gain	1.0000
10:96949007:GACA:G	acceptor_gain	1.0000
10:96952101:AGAC:A	acceptor_gain	1.0000
10:96952102:GACG:G	acceptor_gain	1.0000
10:96832394:GT:G	donor_gain	0.9900
10:96833446:GGCT:G	donor_gain	0.9900
10:96852703:TAG:T	donor_gain	0.9900
10:96852704:AGA:A	donor_gain	0.9900
10:96852729:A:AG	donor_gain	0.9900
10:96852759:A:T	donor_gain	0.9900

AlphaMissense

10298 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:96949080:T:C	F8S	0.999
10:96949257:T:C	L67P	0.999
10:96952112:T:A	L83H	0.999
10:96952112:T:C	L83P	0.999
10:96952118:T:A	L85Q	0.999
10:96952118:T:C	L85P	0.999
10:96949257:T:A	L67H	0.998
10:96949083:C:A	A9D	0.997
10:96949091:T:G	Y12D	0.997
10:96949251:T:C	L65P	0.997
10:96949068:T:C	M4T	0.996
10:96949071:T:A	I5N	0.996
10:96949071:T:C	I5T	0.996
10:96949071:T:G	I5S	0.996
10:96952115:A:G	D84G	0.996
10:96952120:T:C	S86P	0.996
10:96952118:T:G	L85R	0.995
10:96949069:G:A	M4I	0.994
10:96949069:G:C	M4I	0.994
10:96949069:G:T	M4I	0.994
10:96949091:T:C	Y12H	0.994
10:96949251:T:A	L65Q	0.994
10:96949082:G:C	A9P	0.993
10:96949092:A:C	Y12S	0.993
10:96949257:T:G	L67R	0.993
10:96952112:T:G	L83R	0.993
10:96952115:A:C	D84A	0.993
10:96949260:C:T	T68I	0.992
10:96952116:T:A	D84E	0.992
10:96952116:T:G	D84E	0.992

dbSNP variants (sampled 300 via entrez): RS1000010299 (10:96872789 C>T), RS1000063992 (10:96907233 TGTG>T), RS1000072896 (10:96956028 C>G,T), RS1000082100 (10:96872441 C>A), RS1000103876 (10:96830510 T>G), RS1000118769 (10:96834246 C>T), RS1000124378 (10:96851114 G>A), RS1000125630 (10:96926357 C>T), RS1000141694 (10:96956068 A>C,G), RS1000162835 (10:96975559 C>A,G), RS1000181393 (10:96847210 C>T), RS1000198056 (10:96987230 G>A), RS1000204133 (10:96979192 G>A), RS1000256587 (10:96918878 C>T), RS1000280577 (10:96861671 G>C)

Disease associations

OMIM: gene MIM:607698 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST008151_104	Waist circumference	2.000000e-06
GCST008160_106	Waist circumference	2.000000e-06
GCST008551_7	Simvastatin-induced myopathy	6.000000e-06
GCST010605_8	Parent of origin effect on receptive language ability (paternal)	9.000000e-06
GCST012434_2	Peak height velocity	6.000000e-08

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0005686	receptive language perception
EFO:0005939	parental genotype effect measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

52 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	affects binding, increases reaction, increases expression	5
Valproic Acid	affects expression, decreases expression	4
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression, increases expression	2
Aflatoxin B1	increases methylation	2
FR900359	affects phosphorylation	1
TAK-243	decreases sumoylation	1
dicrotophos	increases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	affects binding, affects folding, decreases reaction	1
trichostatin A	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
sodium arsenite	decreases expression	1
benzo(e)pyrene	decreases methylation	1
aflatoxin B2	increases methylation	1
coumarin	decreases phosphorylation	1
1-nitropyrene	increases expression	1
di-n-butylphosphoric acid	affects expression	1
K 7174	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
ICG 001	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
bisphenol S	affects binding, increases reaction	1
jinfukang	decreases expression	1
(+)-JQ1 compound	increases expression	1
bisphenol AF	affects binding, affects folding, decreases reaction	1
Resveratrol	affects cotreatment, decreases expression	1
Leflunomide	increases expression	1
Acetaminophen	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer